Major Depressive Disorder |21-65| Outpatient | Earn up to $2,275
Segal Trials is currently conducting an outpatient Psychedelic clinical research study evaluating the safety and efficacy of an investigational medication based on psilocybin for patients with Depression.
Participants may qualify if they are:
- Adults between 21 and 65 years old
- Diagnosed or experience symptoms of Depression
- Must be on a stable dose of antidepressant medication
- Cannot have had exposure to psilocybin, or any other psychedelics such as ayahuasca, mescaline, LSD, peyote, MDMA, ketamine, or esketamine more than 10 times in the last 10 years or any psychedelic use within 6 months before screening
- Additional Criteria may apply
- Study length: Up to 84 days
Participants who qualify may receive:
- Study-related exams & lab work – at no cost
- Available transportation
- No insurance is necessary
- Compensation up to $2,275 for time and travel if qualified